[Treatment approaches for diffuse large B-cell lymphoma].

Area of Science:

• Hematology
• Oncology
• Immunology

Context:

• Diffuse large B-cell lymphoma (DLBCL) is the most prevalent form of non-Hodgkin lymphoma.
• DLBCL is characterized by significant heterogeneity in its morphologic, immunologic, and cytogenetic features.
• The 2008 WHO classification categorizes DLBCL into distinct subtypes based on clinical, morphological, immunological, and genetic characteristics.

Purpose:

• To review the current treatment strategies for DLBCL.
• To highlight recent clinical trials conducted in Japan focusing on specific DLBCL subgroups.
• To address the unmet needs in managing DLBCL subtypes with suboptimal outcomes.

Summary:

• The standard care for DLBCL involves CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) combined with rituximab (anti-CD20 antibody).
• While this regimen cures many patients, certain DLBCL subtypes still exhibit unsatisfactory clinical outcomes.
• Recent advancements and ongoing research, particularly in Japan, aim to improve treatment efficacy for these challenging subgroups.

Impact:

• Improved understanding of DLBCL heterogeneity and its impact on treatment response.
• Identification of novel therapeutic approaches and clinical trial insights for refractory DLBCL subtypes.
• Potential for enhanced patient survival and quality of life through tailored treatment strategies for specific DLBCL groups.